Ir a las Transacciones
Salud

Dimainvest S.r.l. has launched a voluntary public tender offer for Shedir Pharma Group S.p.A.

Dimainvest S.r.l. has initiated a voluntary public tender offer for the shares of Shedir Pharma Group S.p.A.

Dimainvest is a holding company owned by Umberto Di Maio, the controlling shareholder of Shedir Pharma Group.

Shedir Pharma Group manufactures and distributes nutraceuticals, cosmetics and medical devices. The company is headquartered in Piano di Sorrento, Italy.

Oaklins Italy’s parent company, Banca Akros, acted as the appointed broker for the collection of shares in the voluntary public tender offer for 11.9% of Shedir Pharma Group’s shares by Dimainvest.

PARTES

Contáctese con el equipo de la transacción

Giulio Greco

Director General
Milan, Italia
Oaklins Italy

Nicola Vulcano

Director
Milan, Italia
Oaklins Italy

Marco Valsecchi

Asociado
Milan, Italia
Oaklins Italy

Rita Vizzi

Analista
Milan, Italia
Oaklins Italy

Transacciones relacionadas

Backspin has completed a mandatory public tender offer for the shares of Spindox
Private Equity | TMT

Backspin has completed a mandatory public tender offer for the shares of Spindox

Backspin S.p.A. has completed a mandatory public tender offer for Spindox S.p.A.

Ver más
Rare Patient Voice has been acquired by Konovo
Salud | TMT

Rare Patient Voice has been acquired by Konovo

Rare Patient Voice has been acquired by Konovo, a technology-first healthcare intelligence company backed by Fraser Healthcare Partners.

Ver más
Lindenhofgruppe has sold its majority stake in LabPoint to Affidea Switzerland
Salud

Lindenhofgruppe has sold its majority stake in LabPoint to Affidea Switzerland

LabPoint Medical Laboratories AG has been acquired by Affidea Switzerland AG. Through the transaction, Lindenhofgruppe AG gains a strong strategic partner to support the further development of LabPoint and will remain a shareholder with a reduced stake, continuing as a key customer of the company. It lays the foundation for LabPoint’s sustainable development under a new anchor shareholder, with the aim of further strengthening and selectively expanding its position in laboratory diagnostics.

Ver más